Colorectal cancer (CRC) continues to be a global health concern, necessitating further
research into its complex biology and innovative treatment approaches. The etiology …

Certain genetic alterations and right-sided primary tumor location are associated with
resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer …

Over the past few years, several novel systemic treatments have emerged for patients with
treatment-refractory metastatic colorectal cancer, thus making selection of the most effective …

Pembrolizumab and other immunotherapies have become central in treating metastatic
colon cancer, particularly effective in patients with mismatch repair deficiencies. We report a …

The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus
anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) …

The burden of colorectal cancer (CRC) is high in the Asia‐Pacific region, and several
countries in this region have among the highest and/or fastest growing rates of CRC in the …

Minimal Canadian data are available on the RAS testing rates, treatment patterns, and
corresponding overall survival (OS) in metastatic colorectal cancer (mCRC) patients. We …

Background Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) are standard therapies for
refractory metastatic colorectal cancer (mCRC). No results of large real-world data directly …

Colorectal cancer (CRC) is a global health concern, necessitating adjuvant chemotherapy
post-curative surgery to mitigate recurrence and enhance survival, particularly in …

Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic
colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of …